CEL-SCI CORP
CVMNYSE AMERICANTrading Snapshot
- Day Range
- $1.49 – $1.50
- 52-Week Range
- $0.89 – $13.48
- Volume
- $2.61B
- Avg Volume
- $2.88B
- Shares Outstanding
- 17.5M
- Next Earnings
- Sep 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $513,839
- Last Q Revenue
- $140,267
- P/E Ratio
- —
- P/S Ratio
- 50.7x
- EPS (TTM)
- $-3.58
- Dividend Yield
- —
Why Investors Own CVM
- ✓High-growth profile — revenue up +55.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 30% gross margin and 16% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About CEL-SCI CORP
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
CEL-SCI Announces Publication Of Its Study, 'A Novel Neoadjuvant Immunotherapy Confers Improved Overall Survival In Oral Cancer Patients With Low Tumor PD-L1 Expression: The IT-MATTERS Clinical Trial – Prognostic Role Of Tumor PD-L1 Expression' In Journal Oral Oncology
The published article identified low and zero (0%) PD-L1 expression and no lymph node involvement as biomarkers for selecting patients most likely to benefit from Multikine pre-surgery treatmentStudy concludes Multikine
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.6% to $0.18 during Thursday's regular session. The company's market cap stands at $7.6 million. Agape ATP (NASDAQ:ATPC) shares moved upwards by
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
VIENNA, Va., July 13, 2026--CEL-SCI to launch FDA Registration-Enabling Phase 3 Confirmatory Study to bring Multikine to Market for newly diagnosed head and neck cancer.
CEL-SCI To Launch Phase 3 Confirmatory Study
Patient enrollment expected to commence at clinical centers in the U.S., Europe, Asia and later on in South AmericaThe 212-patient confirmatory study is powered at approximately 97% to confirm a previously observed 0.34